Ryan Schoenfeld, Chief Executive Officer at The Mark Foundation for Cancer Research, shared a post on LinkedIn:
“We can’t cure what we can’t detect. Late-stage diagnosis remains the primary driver of poor survival rates for the world’s deadliest cancers, yet progress in screening technologies has lagged for far too long.
This week, The Mark Foundation for Cancer Research launched a new $12 million coalition in partnership with the American Association for Cancer Research, The Lustgarten Foundation, Break Through Cancer, and The Honorable Tina Brozman Foundation for Ovarian Cancer Research (Tina’s Wish). Together, we are funding six collaborative teams dedicated to solving the most critical challenges in the early detection of pancreatic, ovarian, and esophageal cancers, as well as cancer predisposition syndromes.
These teams are employing truly novel approaches: from utilizing AI to spot early warning signs in the esophagus to developing radioactive imaging tools to reveal ‘invisible’ pancreatic mutations. By pooling our resources and aligning our expertise, we are enabling the kind of cross-disciplinary research that will change the future of cancer diagnosis and care.
Congratulations to this year’s Early Detection Award recipients, including: Nikolaos Sgourakis, Mark Sellmyer, Possu Huang, Brian Wolpin, Andrew Aguirre, Julie Sutcliffe, Laura Wood, Trevor Pugh, Brian Crompton, Paul Northcott, Kara Maxwell, Christina Curtis, Greg Charville, William Grady, Rebecca Fitzgerald, Peter Sorger, David Walt, Sandro Santagata, Ronny Drapkin, Dan-Avi Landau, Paul Mischel and Adam Widman.”
More posts featuring Ryan Schoenfeld.